[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

Valentiner et al., 2008 - Google Patents

[18F] FDG and [18F] FLT PET-CT and MR imaging of human neuroblastomas in a SCID mouse xenograft model

Valentiner et al., 2008

View PDF
Document ID
11920153884833633474
Author
Valentiner U
Haane C
Peldschus K
Gustke H
Brenner W
Wilke F
Pommert A
Owsijewitsch M
Schumacher U
Klutmann S
Publication year
Publication venue
Anticancer research

External Links

Snippet

Background: Finding new therapeutic agents is of great clinical interest in neuroblastoma research because prognosis of children with disseminated stages of disease is still poor. As xenograft mouse models are frequently used for studying anticancer drugs in vivo, small …
Continue reading at ar.iiarjournals.org (PDF) (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus organic compounds
    • A61K51/0493—Steroids, e.g. cholesterol, testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/14—Peptides, e.g. proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/04—X-ray contrast preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Detecting, measuring or recording for diagnostic purposes; Identification of persons
    • A61B5/05—Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radiowaves
    • A61B5/055—Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radiowaves involving electronic or nuclear magnetic resonance, e.g. magnetic resonance imaging
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B6/00—Apparatus for radiation diagnosis, e.g. combined with radiation therapy equipment
    • A61B6/50—Clinical applications
    • A61B6/507—Clinical applications involving determination of haemodynamic parameters, e.g. perfusion CT
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Detecting, measuring or recording for diagnostic purposes; Identification of persons
    • A61B5/72—Signal processing specially adapted for physiological signals or for diagnostic purposes
    • A61B5/7271—Specific aspects of physiological measurement analysis
    • A61B5/7285—Specific aspects of physiological measurement analysis for synchronising or triggering a physiological measurement or image acquisition with a physiological event or waveform, e.g. an ECG signal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients

Similar Documents

Publication Publication Date Title
Mease et al. PET imaging in prostate cancer: focus on prostate-specific membrane antigen
Klumpp et al. Preoperative assessment of peritoneal carcinomatosis: intraindividual comparison of 18F-FDG PET/CT and MRI
Powles et al. Molecular positron emission tomography and PET/CT imaging in urological malignancies
Weber et al. O-(2-[18 F] fluoroethyl)-L-tyrosine and L-[methyl-11 C] methionine uptake in brain tumours: initial results of a comparative study
Schmidt et al. Whole-body MRI for the staging and follow-up of patients with metastasis
Laurent et al. Comparative study of two whole-body imaging techniques in the case of melanoma metastases: advantages of multi-contrast MRI examination including a diffusion-weighted sequence in comparison with PET-CT
Yao et al. Infection imaging with 18F-FDS and first-in-human evaluation
Ng et al. PET/CT and 3-T whole-body MRI in the detection of malignancy in treated oropharyngeal and hypopharyngeal carcinoma
Deng et al. Radiolabeled cyclic arginine-glycine-aspartic (RGD)-conjugated iron oxide nanoparticles as single-photon emission computed tomography (SPECT) and magnetic resonance imaging (MRI) dual-modality agents for imaging of breast cancer
CN108430520A (en) Long-acting gadolinium base cancer target imaging and therapeutic agent
Ell et al. Functional imaging of the brain
Wong et al. A comparison of image contrast with 64Cu-labeled long circulating liposomes and 18F-FDG in a murine model of mammary carcinoma
Hermans et al. Imaging techniques
Lawrentschuk et al. Positron emission tomography (PET), immuno-PET and radioimmunotherapy in renal cell carcinoma: a developing diagnostic and therapeutic relationship.
Yang et al. Preclinical evaluation of an 18 F-trifluoroborate methionine derivative for glioma imaging
Valentiner et al. [18F] FDG and [18F] FLT PET-CT and MR imaging of human neuroblastomas in a SCID mouse xenograft model
Kung et al. Prevalence of detecting unknown cerebral metastases in fluorodeoxyglucose positron emission tomography/computed tomography and its potential clinical impact
US20110300070A1 (en) Biomolecule complexes as contrast agents in positron emission tomography (pet) based methods for the assessment of organ function
Krieger-Hinck et al. Visualisation of neuroblastoma growth in a Scid mouse model using [18F] FDG and [18F] FLT-PET
Hermans et al. Imaging techniques
US12115232B2 (en) Preparation for magnetic resonance diagnostics for oncological diseases, comprising deuterated 3-O-methylglucose, and diagnostic method using said preparation
US20220079905A1 (en) Magnetic resonance imaging drug containing deuterated sarcosine, and diagnostic method using said drug
US12082918B2 (en) Preparation for magnetic resonance diagnostics for oncological diseases, comprising deuterated 2-amino-2-methylpropionic acid and/or 2-(N-methylamino)-2-methylpropionic acid, and diagnostic method using said preparation
van Leeuwen et al. Potential value of color-coded dynamic breast-specific gamma-imaging; comparing 99mTc-(V)-DMSA, 99mTc-MIBI, and 99mTc-HDP in a mouse mammary tumor model
RU2718052C2 (en) Preparation for magnetic resonance diagnostics of oncological diseases containing deuterated 3-o-methylglucose, and diagnostic method using said preparation